All News

Found 538,984 articles

• Elan Corporation PLC Announces Suspension Of Trading Its Shares Commencing March 7, 2006 For Up To Two Days; Suspension Of Trading Due To Two Day FDA Advisory Committee Meeting To Review Tysabri

  3/1/2006

• Study Finds Pfizer Inc.'s Celebrex Raises Heart Attack Risk

  3/1/2006

• Sanofi-Aventis (France) Says U.S. Plavix Trial Postponed

  3/1/2006

• CDC Obtains Children's Confidential Records Without Parental Consent For Autism Study, Says NAA

  3/1/2006

• Popular Painkiller Linked To 2000 Deaths

  3/1/2006

• Pfizer Inc. Completes Acquisition Of Exubera Rights From Sanofi-Aventis (France)

  3/1/2006

• Germans Urged To Watch Pets Amid Bird Flu Scare

  3/1/2006

• 16 Women File Lawsuit Against Boston Lab Acu-Gen Biolab, Inc.

  3/1/2006

• Genta Incorporated Release: Genasense(R) New Drug Application Accepted For Review By FDA

  3/1/2006

• "Nano Skins" Show Promise As Flexible Electronic Devices

  3/1/2006

• New Sensor To Provide Early Warning Of Oxygen Loss To Unborn Children

  3/1/2006

• New Technology For Accelerating Development Of Vaccines Against H5N1 Flu

  3/1/2006

• Cleveland Clinic Foundation Spin-Off Raises $6 Million To Develop Treatments For Atrial Fibrillation

  3/1/2006

• Companies License Real-Time Pathogen Detection Technology Developed At Kent State, NEOUCOM

  3/1/2006

• MorphoSys AG And Roche Expand Therapeutic Antibody Partnership; MorphoSys To Receive Up To $10 Million EURO

  3/1/2006

• The Day In Review: Rituxan From Genentech, Inc. And Biogen Idec, Inc. (Massachusetts) Approved For Arthritis

  3/1/2006

• Generex Biotechnology Corporation Completes Positive Pre-NDS Meeting With Health Canada For Generex Oral-lyn(TM)

  3/1/2006

• Nuvo Research Inc. Provides Update On Long-Term Safety Trial For Pennsaid(R)

  3/1/2006

• Delcath Systems, Inc. Announces Initial Patient Treatment In Phase III Clinical Trial

  3/1/2006

• RxKinetix, Inc. Completes Its End Of Phase 2 Meeting With The FDA For RK-0202 In Oral Mucositis And Is Moving Into Phase 3

  3/1/2006